CYD Dengue Vaccine + Inactivated rabies virus vaccine + Placebo

Phase 2Completed
0 watching 0 views this week Active
51
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dengue Virus

Conditions

Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Diseases

Trial Timeline

Feb 1, 2009 → Feb 1, 2014

About CYD Dengue Vaccine + Inactivated rabies virus vaccine + Placebo

CYD Dengue Vaccine + Inactivated rabies virus vaccine + Placebo is a phase 2 stage product being developed by Sanofi for Dengue Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT00842530. Target conditions include Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00842530Phase 2Completed

Competing Products

20 competing products in Dengue Virus

See all competitors
ProductCompanyStageHype Score
V180 + Alhydrogel™ + PlaceboMerckPhase 1
33
Low-dose V180 with low-dose ISCOMATRIX™ adjuvant + Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant + Medium-dose V180 (non-adjuvanted) + Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant + Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant + Medium-dose V180 with Alhydrogel™ adjuvant + High-dose V180 (non-adjuvanted) + High-dose V180 with low-dose ISCOMATRIX™ adjuvant + High-dose V180 with medium-dose ISCOMATRIX™ adjuvant + Low-dose V180 with high-dose ISCOMATRIX™ adjuvant + Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant + High-dose V180 with high-dose ISCOMATRIX™ adjuvant + PlaceboMerckPhase 1
33
V181 + Butantan - DVMerckPhase 2
52
V181 High-Potency Level + V181 Mid-Potency Level + V181 Low-Potency Level + PlaceboMerckPhase 2
52
EYU688 + PlaceboNovartisPhase 2
52
balapiravir [RO4588161] + placeboRochePhase 1
33
Dengue Tetravalent Vaccine, LiveSanofiPre-clinical
22
CYD Dengue Vaccine (5-dose formulation) + Placebo, NaCl 0.9%SanofiPhase 2
51
Chimeric dengue serotype (1, 2, 3, 4) + Chimeric dengue serotype (1, 2, 3, 4) + Chimeric dengue serotype (1, 2, 3, 4)SanofiPhase 2
51
Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Placebo: NaCl 0.9%SanofiPhase 3
76
Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus + NaCl 0.9% + Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed + Meningococcal A+C vaccineSanofiPhase 2
51
Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus + Yellow FeverSanofiPhase 2
51
Tetravalent CYD Dengue Vaccine , 5555 formulation + Tetravalent CYD Dengue Vaccine , 5553 formulation + Tetravalent CYD Dengue Vaccine, 4444 formulationSanofiPhase 2
51
CYD Dengue Vaccine + Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed + Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbedSanofiPhase 3
76
Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus + Placebo: NaCl 0.9%SanofiPhase 3
76
Live, attenuated, dengue serotype 1, 2, 3, 4 virus + Placebo: (NaCl) 0.9% solutionSanofiPhase 3
76
CYD Dengue Vaccine + CYD Dengue Vaccine + Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.SanofiPhase 3
76
CYD dengue vaccine serotypes (1, 2, 3, 4). + Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharideSanofiPhase 2
51
CYD Dengue Vaccine + Placebo (Sodium chloride 0.9%)SanofiPhase 2
51
Live, attenuated, dengue serotype 1, 2, 3, 4 virus + Placebo: Sodium chloride (NaCl) 0.9%SanofiPhase 3
76